ScoreComparison
Why is Protalix Biotherapeutics, Inc. ?
Unrated Stock - No Analysis Available
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Protalix Biotherapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-0.84%
EBIT Growth (5y)
22.69%
EBIT to Interest (avg)
-0.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.74
Sales to Capital Employed (avg)
1.17
Tax Ratio
24.19%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
16.98%
ROCE (avg)
58.62%
ROE (avg)
6.33%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
32
Industry P/E
Price to Book Value
2.78
EV to EBIT
19.98
EV to EBITDA
15.52
EV to Capital Employed
7.78
EV to Sales
1.55
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
38.92%
ROE (Latest)
8.64%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend15What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -2.19 MM
NET SALES(HY)
At USD 25.77 MM has Grown at 49.64%
NET PROFIT(HY)
At USD -3.46 MM has Grown at 49.18%
RAW MATERIAL COST(Y)
Fallen by -113.43% (YoY
-6What is not working for the Company
PRE-TAX PROFIT(Q)
At USD 0.66 MM has Fallen at -48.71%
NET PROFIT(Q)
At USD 0.16 MM has Fallen at -83.21%
Here's what is working for Protalix Biotherapeutics, Inc.
Operating Cash Flow
Highest at USD -2.19 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
At USD 25.77 MM has Grown at 49.64%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Raw Material Cost
Fallen by -113.43% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Protalix Biotherapeutics, Inc.
Pre-Tax Profit
At USD 0.66 MM has Fallen at -48.71%
over average net sales of the previous four periods of USD 1.29 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD 0.16 MM has Fallen at -83.21%
over average net sales of the previous four periods of USD 0.98 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
